Probiotic Strains and Intervention Total Doses for Modulating Obesity-Related Microbiota Dysbiosis: A Systematic Review and Meta-analysis
Metadatos
Mostrar el registro completo del ítemAutor
López Moreno, Ana; Suárez, Antonio; Avanzi, Camila; Monteoliva Sánchez, Mercedes; Aguilera Gómez, MargaritaEditorial
MDPI
Materia
Obesity Metabolic disorders Probiotics Strains Doses Intervention Obesogens
Fecha
2020-06-29Referencia bibliográfica
López-Moreno, A., Suárez, A., Avanzi, C., Monteoliva-Sánchez, M., & Aguilera, M. (2020). Probiotic Strains and Intervention Total Doses for Modulating Obesity-Related Microbiota Dysbiosis: A Systematic Review and Meta-analysis. Nutrients, 12(7), 1921.[doi:10.3390/nu12071921]
Patrocinador
Programme "Intensificacion de la Investigacion" University of Granada (2019-2020); UGR Plan Propio de Investigacion 2019-2020; University of Granada BIO-190; Junta de Andalucia BIO-190Resumen
Obesity is a growing health threat worldwide. Administration of probiotics in obesity
has also parallelly increased but without any protocolization. We conducted a systematic review
exploring the administration pattern of probiotic strains and effective doses for obesity-related
disorders according to their capacity of positively modulating key biomarkers and microbiota
dysbiosis. Manuscripts targeting probiotic strains and doses administered for obesity-related
disorders in clinical studies were sought. MEDLINE, Scopus, Web of Science, and Cochrane
Library databases were searched using keywords during the last fifteen years up to April 2020.
Two independent reviewers screened titles, abstracts, and then full-text papers against inclusion
criteria according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)
guidelines. From 549 interventional reports identified, we filtered 171 eligible studies, from which
24 full-text assays were used for calculating intervention total doses (ITD) of specific species and
strains administered. Nine of these reports were excluded in the second-step because no specific data
on gut microbiota modulation was found. Six clinical trials (CT) and 9 animal clinical studies were
retained for analysis of complete outcome prioritized (body mass index (BMI), adiposity parameters,
glucose, and plasma lipid biomarkers, and gut hormones). Lactobacillus spp. administered were
double compared to Bifidobacterium spp.; Lactobacillus as single or multispecies formulations whereas
most Bifidobacteria only through multispecies supplementations. Differential factors were estimated
from obese populations’ vs. obesity-induced animals: ITD ratio of 2 × 106 CFU and patterns of
administrations of 11.3 weeks to 5.5 weeks, respectively. Estimation of overall probiotics impact
from selected CT was performed through a random-effects model to pool effect sizes. Comparisons
showed a positive association between the probiotics group vs. placebo on the reduction of BMI, total
cholesterol, leptin, and adiponectin. Moreover, negative estimation appeared for glucose (FPG) and
CRP. While clinical trials including data for positive modulatory microbiota capacities suggested that
high doses of common single and multispecies of Lactobacillus and Bifidobacterium ameliorated key
obesity-related parameters, the major limitation was the high variability between studies and lack of
standardized protocols. Efforts in solving this problem and searching for next-generation probiotics
for obesity-related diseases would highly improve the rational use of probiotics.